Paris-based WhiteLab Genomics raises €23.2 million to accelerate AI-driven genomic medicine development
WhiteLab Genomics, a Paris-based BioTech company that uses AI to design the building blocks of genomic medicines, has closed a €23.2 million ($26 million) Series B funding round. The round was led by AVP, an independent global investment platform managing over €2.5 billion in assets. The round also saw participation from new investors Yaday Health […] The post Paris-based WhiteLab Genomics raises…
Paris-based WhiteLab Genomics, a biotech company utilizing artificial intelligence to design genomic medicines, has secured €23.2 million ($26 million) in Series B funding. The investment round was spearheaded by AVP, a global investment firm managing €2.5 billion in assets, alongside participation from new investors Yaday Health and Blast Club, as well as existing backers Omnes Capital and Debiopharm Innovation Fund.
David Del Bourgo, co-founder and CEO of WhiteLab Genomics, stated that the company's AI-driven approach designs genomic medicines that function in vivo, rather than just on paper, marking a significant impact on the field. The funds will be utilized to expand in vivo validation efforts, strengthen partnerships in North America, and explore opportunities in Japan and South Korea.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
